{"id":850857,"date":"2025-05-14T08:07:01","date_gmt":"2025-05-14T12:07:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/"},"modified":"2025-05-14T08:07:01","modified_gmt":"2025-05-14T12:07:01","slug":"inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/","title":{"rendered":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference"},"content":{"rendered":"
\n

BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc.<\/b><\/a>\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY.<\/p>\n

\n 2025 RBC Capital Markets Global Healthcare Conference<\/b>\n <\/p>\n

May 20-21, 2025
Format: Fireside Chat and 1-on-1 virtual meetings
Presentation Time: 11:00am EDT<\/p>\n

\n About\u00a0INmune Bio Inc.<\/strong>\n <\/p>\n

\n INmune\u00a0Bio\u00a0Inc.<\/a>\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer\u2019s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro\u2122). The Natural Killer Cell Priming Platform includes INKmune\u00ae\u00a0developed to prime a patient\u2019s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom\u2122<\/u>, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal\/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio\u2019s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit\u00a0www.inmunebio.com<\/a>.<\/p>\n

\n Forward\u00a0Looking\u00a0Statements<\/strong>\n <\/p>\n

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom\u2122, XPro1595 (XPro\u2122), and INKmune\u00ae\u2122 are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company\u2019s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company\u2019s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company\u2019s filings with the Securities and Exchange Commission, including the Company\u2019s Annual Report on Form 10-K, the Company\u2019s Quarterly Reports on Form 10-Q and the Company\u2019s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.<\/p>\n

\n David Moss<\/b>
\n
\n
\n <\/b>
\n Co-founder and Chief Financial Officer<\/b>
\n
\n
\n <\/b>
\n (561) 710-0512<\/b>
\n
\n
\n <\/b>
\n
\n info@inmunebio.com<\/b>
\n <\/a>
\n <\/p>\n

<\/b>
\n Daniel Carlson<\/b>
\n
\n
\n <\/b>
\n Head of Investor Relations<\/b>
\n
\n
\n <\/b>
\n (415) 509-4590<\/b>
\n
\n
\n <\/b>
\n
\n dcarlson@inmunebio.com<\/b>
\n <\/a>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY. 2025 RBC Capital Markets Global Healthcare Conference May 20-21, 2025Format: Fireside Chat and 1-on-1 virtual meetingsPresentation Time: 11:00am EDT About\u00a0INmune Bio Inc. INmune\u00a0Bio\u00a0Inc.\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, … <\/p>\n

Continue reading “INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-850857","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nINmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY. 2025 RBC Capital Markets Global Healthcare Conference May 20-21, 2025Format: Fireside Chat and 1-on-1 virtual meetingsPresentation Time: 11:00am EDT About\u00a0INmune Bio Inc. INmune\u00a0Bio\u00a0Inc.\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, … Continue reading "INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-14T12:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference\",\"datePublished\":\"2025-05-14T12:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/\"},\"wordCount\":623,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/\",\"name\":\"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==\",\"datePublished\":\"2025-05-14T12:07:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk","og_description":"BOCA RATON, Fla., May 14, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc.\u00a0(NASDAQ: INMB) (the \u201cCompany\u201d), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces that the Company will be presenting at the 2025 RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, at the InterContinental Barclay NY. 2025 RBC Capital Markets Global Healthcare Conference May 20-21, 2025Format: Fireside Chat and 1-on-1 virtual meetingsPresentation Time: 11:00am EDT About\u00a0INmune Bio Inc. INmune\u00a0Bio\u00a0Inc.\u00a0is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, … Continue reading \"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-14T12:07:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference","datePublished":"2025-05-14T12:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/"},"wordCount":623,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/","name":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==","datePublished":"2025-05-14T12:07:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MDU2MCM2OTM4ODExIzUwMDA2ODMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inmune-bio-inc-announces-attendance-at-the-2025-rbc-capital-markets-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850857","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=850857"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/850857\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=850857"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=850857"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=850857"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}